title: Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart.
abstract: BACKGROUND
  The regulation and interaction of ACE and the angiotensin II (Ang II) type I (AT1) receptor in the failing human heart are not understood.
  
  
  RESULTS
  Radioligand binding with 3H-ramiprilat was used to measure ACE protein in membrane preparations of hearts obtained from 36 subjects with idiopathic dilated cardiomyopathy (IDC), 8 subjects with primary pulmonary hypertension (PPH), and 32 organ donors with normal cardiac function (NF hearts). 125I-Ang II formation was measured in a subset of hearts. Saralasin (125I-(Sar1,Ile8)-Ang II) was used to measure total Ang II receptor density. AT1 and AT2 receptor binding were determined with the AT1 receptor antagonist losartan. Maximal ACE binding (Bmax) was 578+/-47 fmol/mg in IDC left ventricle (LV), 713+/-97 fmol/mg in PPH LV, and 325+/-27 fmol/mg in NF LV (P<0.001, IDC or PPH versus NF). In IDC, PPH, and NF right ventricles (RV), ACE Bmax was 737+/-78, 638+/-137, and 422+/-49 fmol/mg, respectively (P=0.02, IDC versus NF; P=0.08, PPH versus NF). 125I-Ang II formation correlated with ACE binding sites (r=0.60, P=0.00005). There was selective downregulation of the AT1 receptor subtype in failing PPH ventricles: 6.41+/-1.23 fmol/mg in PPH LV, 2.37+/-0.50 fmol/mg in PPH RV, 5.38+/-0.53 fmol/mg in NF LV, and 7.30+/-1.10 fmol/mg in NF RV (P=0.01, PPH RV versus PPH LV; P=0.0006, PPH RV versus NF RV).
  
  
  CONCLUSIONS
  ACE binding sites are increased in both failing IDC and nonfailing PPH ventricles. In PPH hearts, the AT1 receptor is downregulated only in the failing RV.
authors.affiliation: Department of Medicine, Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado, USA. lzishman@rush.edu
authors.forename: L S
authors.initials: LS
authors.lastname: Zisman
authors.forename: K
authors.initials: K
authors.lastname: Asano
authors.forename: D L
authors.initials: DL
authors.lastname: Dutcher
authors.forename: A
authors.initials: A
authors.lastname: Ferdensi
authors.forename: A D
authors.initials: AD
authors.lastname: Robertson
authors.forename: M
authors.initials: M
authors.lastname: Jenkin
authors.forename: E W
authors.initials: EW
authors.lastname: Bush
authors.forename: T
authors.initials: T
authors.lastname: Bohlmeyer
authors.forename: M B
authors.initials: MB
authors.lastname: Perryman
authors.forename: M R
authors.initials: MR
authors.lastname: Bristow
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000328:Adult; D002311:Cardiomyopathy, Dilated / Q000378:metabolism*; D020134:Catalytic Domain; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D011869:Radioligand Assay; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D007703:Peptidyl-Dipeptidase A; D000262:Adenylyl Cyclases